What is a lung nodule and how is it monitored or treated?
A lung nodule is a small spot in the lung that is usually benign, but about one in five turns out to be cancer, so care is matched to risk.
Covers: This page explains what a lung nodule is, how it is found, and how doctors decide between monitoring and treatment. It covers common causes, follow-up imaging, biopsy, and surgery, but does not give individual medical advice or cover every rare lung condition.
Also answers: What is a lung nodule? · Lung nodule monitoring and treatment · Are lung nodules cancer? · How often should lung nodules be checked?
- One page for this question6 other ways of asking lead here
- 6 independent sourcesEvery claim links to what supports it
- 1 connected page1 changed this week
- Clean discussionScreened before anything appears
Before you read, make a guess
Fill in the blank: ?% of lung nodules that turn out to be malignant cancer
Drag the slider to fill in the blank
The short answer
Evidence-backed AI-prepared starting mapA lung nodule (pulmonary nodule) is a relatively small focal density in the lung: a solitary pulmonary nodule is a mass smaller than 3 cm in diameter, and a micronodule is under 3 mm; lesions larger than 3 cm are instead called masses. Nodules are frequently found incidentally — in up to 0.2% of chest X-rays and around 1% of CT scans — and most commonly represent a benign tumour such as a granuloma or hamartoma, though roughly 20% turn out to be malignant cancer, especially in older adults and smokers. Management is risk-stratified: CT surveillance for low-risk nodules, PET-CT and/or biopsy for intermediate-risk nodules, and surgical resection for selected high-risk nodules.123
- Evidence 25
Did this answer your question?
Be the first to voteIn brief
Most nodules are benign — commonly granulomas or hamartomas — but around 20% are malignant cancer, especially in older adults and smokers.1
Evidence-backedNodules are usually found incidentally: in up to 0.2% of chest X-rays and around 1% of CT scans.1
Evidence-backedManagement is risk-stratified: CT surveillance for low-risk nodules, PET-CT and/or biopsy for intermediate-risk, and surgery for selected high-risk nodules.3
Evidence-backedSolid nodules stable for 2 years are considered benign, but subsolid nodules need longer stability and carry a higher malignancy risk, especially if a solid component develops or enlarges.3
Evidence-backed
At a glance
The picture in numbers
Live · updated just now
- chest X-rays0.2%
- CT scans1%
20%
20 in every 100
- micronodule3 cm
- nodule3 cm
- mass3 cm
2 years
The evidence behind it
6 sources- Reviews of many studies1
- Other studies and data2
- Background3
Published in 2026
| Source | Kind | Year |
|---|---|---|
| Pulmonary Nodules. | Other studies and data | 2026 |
| Biology, detection, and management of incidental pulmonary nodules: the emerging role of targeted treatments. A review of the current literature and future perspectives. | Reviews of many studies | 2026 |
| ACR Appropriateness Criteria® Indolent Lung Cancer. | Other studies and data | 2026 |
| Lung nodule (Wikipedia) | Background | Unknown |
| Nodule (medicine) (Wikipedia) | Background | Unknown |
| Pope Leo to have surgery after lump found on lung | Background | 2026 |
The community around it
No one has added to this page yet. Firsthand experience, a newer study or a different reading of the numbers would show up here, credited to you.
What it means for you
Which fits you?
Pick the situation closest to yours. Each answer says what it rests on.
If you have just been told a nodule was found incidentally on a scan
the first useful step is comparison with any previous imaging, since comparing current and previous studies is essential to assessing malignancy risk.3
Evidence-backedIf your nodule is classified as low risk
CT surveillance is the indicated approach rather than immediate invasive testing.3
Evidence-backedIf your nodule is classified as intermediate risk
PET-CT, biopsy, or both are indicated to clarify whether it is malignant.3
Evidence-backedIf your nodule is selected as high risk
surgical resection is the indicated option.3
Evidence-backedIf you have a solid nodule that has been stable for 2 years
it is considered benign, whereas a subsolid nodule needs a longer period of stability before it can be called benign.3
Evidence-backedIf you have a subsolid nodule
expect longer follow-up, because these grow more slowly but carry a higher risk of malignancy, especially if a solid component develops or enlarges.3
Evidence-backedIf you have a history of smoking or your nodule is growing
the possibility of cancer may need to be excluded through further radiological studies and interventions, possibly including surgical resection.1
Evidence-backedIf your clinical team has decided to delay intervention
imaging surveillance follows evidence-based appropriateness criteria rather than a one-off scan, and a diagnostic workup or biopsy at that point would be treatment planning, not surveillance.6
Evidence-backedThe full story · 4 chapters
01
What a lung nodule is and how it is found
AI summary:Defines a lung nodule as a focal lung density under 3 cm, notes micronodules and masses, and explains most are found incidentally on scans.
Evidence-backed: A lung nodule is a relatively small focal density in the lung. A solitary pulmonary nodule is a mass in the lung smaller than 3 cm in diameter, while a pulmonary micronodule is under 3 mm; there may also be multiple nodules. In pulmonology, a nodule seen on radiography is a round, focal opacity in lung tissue of less than 3 cm, with larger lesions termed masses. Definitions vary by specialty — in dermatology, for example, nodules are usually greater than 1 cm — so the term is not used identically across medicine.12
Evidence-backed: Most nodules are found incidentally rather than because of symptoms. One or more lung nodules appear as an incidental finding in up to 0.2% of chest X-rays and around 1% of CT scans. Incidental detection is increasing with advances in imaging techniques and the expanded use of CT scans for thoracic evaluation.14
Evidence-backed: A recent example of how nodules surface: the 71-year-old pontiff Pope Leo was reported to be having surgery after a lump was found on his lung, which he said was identified "at a very early stage".5
Have you ever been told you have a lung nodule?
Join free to voteAlready a member? Sign inYour individual answer is private. Only totals are shown.
02
Benign or cancer: why the distinction matters
AI summary:Most nodules are benign granulomas or hamartomas, but about 20% are malignant, so risk assessment guides whether cancer must be ruled out.
Evidence-backed: The nodule most commonly represents a benign tumour such as a granuloma or hamartoma, but in around 20% of cases it represents a malignant cancer, especially in older adults and smokers. Conversely, 10 to 20% of patients with lung cancer are diagnosed in this way. Lung cancer is the leading cause of cancer-related deaths globally, and early diagnosis and treatment are important for improving prognosis, so distinguishing benign from malignant nodules is key to improving outcomes.14
Evidence-backed: Risk assessment starts with comparison to previous imaging. A comparison of current and previous imaging studies, when available, is essential to assess the risk of the nodule being malignant. Prediction models that stratify the risk of malignancy can be used to guide management of solid nodules. If the patient has a history of smoking or the nodule is growing, the possibility of cancer may need to be excluded through further radiological studies and interventions, possibly including surgical resection.31
03
Monitoring: surveillance and stability
AI summary:Low-risk nodules get CT surveillance; solid nodules stable for 2 years are benign, while subsolid nodules need longer follow-up.
Evidence-backed: Management strategies differ according to the type of nodule. Solid nodules that have been stable for 2 years are considered benign, whereas subsolid nodules require a longer period of stability to be considered benign. Computed tomographic (CT) surveillance is indicated for low-risk nodules.3
Evidence-backed: Subsolid nodules are often slower growing than solid nodules but are associated with a higher risk of being malignant, especially if a solid component develops or progressively enlarges. This is why they need longer follow-up before being called benign.3
Evidence-backed: Surveillance is a deliberate choice to delay intervention, not a substitute for it. Where the clinical team determines that treatment is necessary, a diagnostic imaging workup and a biopsy are typically indicated and should not be considered part of surveillance. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for imaging surveillance of indolent pulmonary nodules in patients for whom the clinical team has chosen to delay intervention; they are reviewed annually by a multidisciplinary expert panel and use established methods such as GRADE and the RAND/UCLA Appropriateness Method.6
04
Biopsy and treatment
AI summary:Intermediate-risk nodules need PET-CT, biopsy, or both, and selected high-risk nodules need surgery, balancing timely diagnosis against unnecessary procedures.
Evidence-backed: For intermediate-risk nodules, positron-emission tomography-CT, biopsy, or both are indicated; for selected high-risk nodules, surgical resection is indicated. Biopsy methods include transthoracic needle biopsy and navigational bronchoscopy. Current management guidelines differ by nodule type and involve biopsy to determine the malignancy status of the nodule.34
Evidence-backed: The goal of the whole pathway is balance: optimal overall management balances timely diagnosis in persons who have cancer with the avoidance of unnecessary invasive procedures in persons who have benign disease.3
Evidence-backed: Beyond surgery, research is examining the role of oncogenic driver mutations in the biology of pulmonary nodules and the targeted treatment of oncogene-driven nodules. This is described as an emerging area, with evidence gaps and areas for future research still being discussed.4
Your turn
Have your say
See where others stand. Join free to add your perspective. One answer per account.
How do you feel about this?
No votes yetQuick questions from connected pages
Before you go
What to remember
Try to recall each hidden figure before you reveal it. Remembering, not rereading, is what makes it stick.
A lung nodule is a small focal density in the lung, under cm in diameter; under 3 mm it is called a micronodule, and larger lesions are termed masses.
Most nodules are benign — commonly granulomas or hamartomas — but around are malignant cancer, especially in older adults and smokers.
Nodules are usually found incidentally: in up to of chest X-rays and around 1% of CT scans.
Your reading
0 of 4 chaptersThis answer keeps changing
When new evidence or a better source comes in, this page is updated (it's on version 2, last changed 59 minutes ago). Follow it to be told when that happens.
Ask this Sylo
Still wondering about something?
Answers come only from this page's reviewed material, with citations, and say plainly when the page doesn't cover it yet.
Behind this page
Who's adding to it, where it comes from, how it changed and what would make it better. Always open to everyone.
Discussion
Sources
Numbers match the citations in the article. A working link isn't proof that a page supports a claim; check the quoted passage and date.
- 1Lung nodule (Wikipedia)WikipediaPublished Sep 29, 2026Checked Oct 11, 2026
“A lung nodule or pulmonary nodule is a relatively small focal density in the lung. A solitary pulmonary nodule (SPN) or coin lesion, is a mass in the lung smaller than three centimeters in diameter. A pulmonary micronodule has a diameter of less than three millimetres. There may also be multiple nodules. One or more lung nodules can be an incidental finding found in up to 0.2% of chest X-rays and around 1% of CT scans. The nodule most commonly represents a benign tumor such as a granuloma or hamartoma, but in around 20% of cases it represents a malignant cancer, especially in older adults and smokers. Conversely, 10 to 20% of patients with lung cancer are diagnosed in this way. If the patient has a history of smoking or the nodule is growing, the possibility of cancer may need to be excluded through further radiological studies and interventions, possibly including surgical resection. The prognosis depends on the underlying condition.”
- 2Nodule (medicine) (Wikipedia)WikipediaPublished Sep 29, 2026Checked Oct 11, 2026
“In medicine, a nodule is a small, discrete lump or growth that is different from surrounding tissue. They are often detected by medical imaging and can be either benign or malignant. Definitions vary by medical specialty. In dermatology, nodules are usually greater than 1 cm in diameter, in contrast to raised, soft bumps of less than 1 cm, which are termed papules, and to cysts, which contain fluid. In pulmonology, when imaging the lungs by radiography, a nodule is a round, focal opacity in the lung tissue of less than 3 cm in diameter, with lesions larger than that instead termed masses. In endocrinology, a thyroid nodule is a lump formed by abnormal growth. Nodules in skin include dermatofibroma and pyogenic granuloma. Nodules may form on tendons and muscles in response to injury, and are frequently found on vocal cords. They may occur in organs such as the lung, or thyroid, or be a sign in other medical conditions such as rheumatoid arthritis.”
- 3Pulmonary Nodules.The New England journal of medicine (Callister & Silvestri)Published Sep 1, 2026Checked Oct 11, 2026
“Management strategies differ according to the type of nodule. A comparison of current and previous imaging studies, when available, is essential to assess the risk of the nodule being malignant. Solid nodules that have been stable for 2 years are considered to be benign, whereas subsolid nodules require a longer period of stability to be considered benign. Prediction models to stratify the risk of the nodule being malignant can be used to guide the management of solid nodules. Computed tomographic (CT) surveillance is indicated for low-risk nodules; positron-emission tomography-CT, biopsy, or both for intermediate-risk nodules; and surgical resection for selected high-risk nodules. Subsolid nodules are often slower growing than solid nodules but are associated with a higher risk of being malignant, especially if a solid component develops or progressively enlarges. Biopsy methods include transthoracic needle biopsy and navigational bronchoscopy. Optimal overall management balances timely diagnosis in persons who have cancer with the avoidance of unnecessary invasive procedures in persons who have benign disease.”
- 4Biology, detection, and management of incidental pulmonary nodules: the emerging role of targeted treatments. A review of the current literature and future perspectives.Lung cancer (Amsterdam, Netherlands) (Soo et al.)Published Aug 3, 2026Checked Oct 11, 2026
“Lung cancer is the leading cause of cancer-related deaths globally, and early diagnosis and treatment are important for improving prognosis. Pulmonary nodules (PNs) are small pulmonary lesions frequently identified during clinical practice, with incidental detection increasing due to advances in imaging techniques and the expanded use of computed tomography scans for thoracic evaluation. The majority of incidental PNs (IPNs) are benign, however some represent early-stage lung cancer, therefore distinguishing benign from malignant IPNs is key to improving lung cancer outcomes. Current management guidelines differ by nodule type and involve biopsy to determine the malignancy status of the nodule. Here, we review current knowledge on the classification, prevalence, and detection of PNs, as well as the current management and risk stratification of PNs. We outline the role of oncogenic driver mutations in the pathobiology of PNs and assess current literature on targeted treatment of oncogene-driven PNs. Finally, we discuss evidence gaps and areas for future research.”
- 5Pope Leo to have surgery after lump found on lungBBC NewsPublished Oct 11, 2026Checked Oct 11, 2026
“The 71-year-old pontiff said the nodule was identified "at a very early stage".”
- 6ACR Appropriateness Criteria® Indolent Lung Cancer.Journal of the American College of Radiology : JACR (Expert et al.)Published Aug 10, 2026Checked Oct 11, 2026
“If the team determines that treatment is necessary, a diagnostic imaging workup and a biopsy are typically indicated and should not be considered part of surveillance. Therefore, this document aims to outline evidence-based guidelines specifically for imaging surveillance of indolent pulmonary nodules in patients for whom the clinical team has chosen to delay intervention. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.”
How it changed
Published 1 time since Oct 11, 2026.
- Version 2Oct 11, 2026Live now
AI-prepared Starting Map from live research.
- First published version.
Help improve it
The brief is open about what's uncertain. These are the specific gaps that new material would fill.
Open questions
How often does a nodule under surveillance actually grow, and how often does growth turn out to be cancer rather than a benign change?
No answers yet
How often are biopsies of lung nodules inconclusive or complicated, and what happens when the result is unclear?
No answers yet
How long must a subsolid nodule remain stable before it can be considered benign, and how much does that vary between patients?
No answers yet
What is the evidence that targeted treatment of oncogene-driven nodules changes outcomes compared with surveillance or surgery?
No answers yet
What is it like to live with a nodule under surveillance — the anxiety, the scan schedule, and the decisions along the way?
No answers yet
Around this topic
Sylos connect: narrower topics report up to broader ones, so what's learned in one place shows up where it matters.